Divergent CRO, founded by Abiel Obanjo and Shawn Williams, earns recognition as one of Life Sciences Review’s "10 Preeminent CROs 2024" for its pioneering approach to enhancing diversity, equity, and inclusion in clinical trials, focusing on BIPOC communities.
-- Founded by Obanjo and Williams, Divergent CRO was established with the mission to ensure that clinical research reflects the diverse populations it serves. Inspired by their personal experiences with healthcare disparities within their families, both founders are committed to eliminating the barriers that prevent BIPOC individuals from fully participating in clinical trials. Their efforts are focused on changing the current dynamics of clinical research, which has historically neglected the needs and unique health challenges of these communities.
Divergent CRO Earns Prestigious Industry Recognition for Advancing Diversity in Clinical Trials
Divergent CRO, a clinical research organization co-founded by Abiel Obanjo and Shawn Williams, has been recognized as one of Life Sciences Review’s "10 Preeminent CROs 2024" for its significant contributions to promoting diversity, equity, and inclusion in clinical research. This recognition highlights the company's groundbreaking efforts to address the underrepresentation of Black, Indigenous, and People of Color (BIPOC) communities in clinical trials, a critical issue in the healthcare and pharmaceutical industries.
Shaping the Future of Inclusive Medical Research
Divergent CRO’s approach to clinical trials stands apart from other clinical research organizations due to its dedicated focus on engaging underrepresented communities. The organization’s innovative strategies include culturally tailored recruitment processes, community outreach programs, and collaborations with healthcare leaders to establish trust and ensure that all patients feel respected and valued. By emphasizing diversity and inclusion, Divergent CRO is not just increasing participation but ensuring that research is relevant, accurate, and applicable across diverse populations.
The company’s recognition by Life Sciences Review further solidifies its position as a leader in fostering inclusive healthcare practices. This acknowledgment comes after extensive evaluation by industry experts who recognized Divergent CRO’s exceptional impact on improving the inclusivity and quality of clinical trials.
A Personal Commitment to Changing Healthcare Outcomes
For both Obanjo and Williams, the mission behind Divergent CRO is deeply personal. Abiel Obanjo’s dedication to clinical research grew from his grandmother’s battle with Alzheimer’s disease, where he witnessed firsthand the need for more research into diseases affecting underserved communities. Similarly, Shawn Williams was motivated by her grandmother's struggle with a rare cancer, highlighting the limited treatment options available due to the lack of diversity in clinical trials. These personal stories have driven the founders to create a company that will not only improve clinical research but also impact real-world healthcare outcomes.
Impact on the Future of Healthcare
The recognition of Divergent CRO as one of the "10 Preeminent CROs 2024" is more than just an industry accolade—it is a testament to the importance of including diverse populations in medical research. The company’s dedication to diversity enhances the validity and applicability of research findings, ultimately leading to more effective treatments for a broader range of patients. As clinical research continues to evolve, Divergent CRO’s inclusive model is setting a new standard for how clinical trials should be designed and executed.
With a growing reputation within the industry and continued efforts to address healthcare disparities, Divergent CRO is well-positioned to drive lasting change in clinical research. Its work promises to shape the future of healthcare by ensuring that treatments are effective for all patients, regardless of background.
About Divergent CRO
Divergent CRO is a clinical research organization focused on improving diversity, equity, and inclusion in clinical trials. Co-founded by Abiel Obanjo and Shawn Williams, the organization aims to address the historical underrepresentation of Black, Indigenous, and People of Color (BIPOC) communities in medical research. By employing innovative strategies to engage these communities, Divergent CRO is working to ensure that clinical trials are representative of global populations, ultimately leading to more effective and inclusive healthcare solutions.
Media Contact
Shawn Williams
Co-founder
Divergent CRO
Phone: +1 (925) 804-3996
Business Phone: +1 (888) 342-1447
Email: swilliams@divergentcro.com
Social Media:
LinkedIn
Instagram
TikTok
YouTube
Contact Info:
Name: Shawn Williams
Email: Send Email
Organization: Divergent CRO
Website: https://divergentcro.com/
Release ID: 89147941
If there are any errors, inconsistencies, or queries arising from the content contained within this press release that require attention or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our reliable team will be available to promptly respond within 8 hours, taking proactive measures to rectify any identified issues or providing guidance on the removal process. Ensuring accurate and dependable information is our top priority.
